Full-Time

Lab Operations Specialist

Chemistry

Updated on 9/3/2026

Abiologics

Abiologics

11-50 employees

AI-driven programmable biologics for therapeutics

Compensation Overview

$72k - $103k/yr

+ Annual incentive program

Watertown, MA, USA

In Person

Bachelor's, Master's

Category
Operations & Logistics (1)
Required Skills
Microsoft Office
Inventory Management
Biochemistry

Get referred to Abiologics

See people who can refer or advise you

Requirements
  • A Bachelor of Science or Master of Science degree, or equivalent experience, in chemistry, chemical engineering, or biochemistry.
  • At least 4 years of experience in a biotechnology, pharmaceutical, or academic research laboratory.
  • Experience with laboratory instrumentation maintenance and general laboratory operations.
  • Experience managing laboratory inventory systems and compound or sample management.
  • Strong organizational skills and exceptional attention to detail.
  • Proficiency with Microsoft Office and laboratory information management or inventory systems.
  • Excellent communication and interpersonal skills, with the ability to work effectively across multidisciplinary teams.
Responsibilities
  • Collaborate daily with chemists, biologists, protein engineers, automation scientists, and computational researchers to enable high-quality science across the organization.
  • Partner with researchers and vendors to maximize laboratory uptime and ensure critical discovery platforms remain available.
  • Strategically plan instrument maintenance, upgrades, and repairs for HPLC-MS, high-resolution mass spectrometers, peptide synthesizers, biolayer interferometry systems, and related equipment.
  • Oversee waste disposal and ensure compliance with laboratory safety and environmental regulations.
  • Identify opportunities to streamline laboratory workflows through process improvements, automation, and adoption of new laboratory technologies.
  • Build and continuously improve systems that enable scientists to rapidly access compounds, reagents, and research materials.
  • Develop and oversee efficient systems for managing compounds and research samples throughout their lifecycle.
  • Maintain accurate digital records that support sample traceability and research reproducibility.
  • Perform periodic inventory audits and reconcile discrepancies.

Abiologics develops a new class of programmable medicines called supranatural biologics to treat a wide range of diseases. By combining artificial intelligence with chemistry, the company designs these therapeutics to be more precise and effective than traditional treatments. Unlike many biotech firms that focus on a single drug, Abiologics uses a multidisciplinary platform to build a toolkit of proprietary biologics that it licenses to pharmaceutical partners. The company's goal is to systematically expand the possibilities of modern medicine by creating a scalable library of programmable treatments for healthcare providers.

Company Size

11-50

Company Stage

Early VC

Total Funding

$50M

Headquarters

Cambridge, Massachusetts

Founded

2020

Get referred to Abiologics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Maria-Chiara Magnone joined as CSO in September 2024, adding J&J drug-development credibility.
  • Abiologics launched with $50 million and Flagship's $3.6 billion startup-creation firepower.
  • Its platform promises oral delivery and tissue access that injectable biologics still miss.

What critics are saying

  • Abiologics still lacks disclosed clinical candidates, leaving platform risk unresolved in 2026.
  • Single-source financing from Flagship concentrates survival risk if Fund VIII priorities shift.
  • Competitive incumbents like Moderna and Generate Biomedicines can outspend Abiologics on AI biologics.

What makes Abiologics unique

  • Flagship built Abiologics over three years; $50 million funds a new Synteins modality.
  • Synteins use AI-designed artificial building blocks, beyond nature's 20 amino acids.
  • Platform targets oral, stable, immune-evasive biologics for oncology, immunology, and metabolic diseases.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

8%

2 year growth

8%
Citybiz
Sep 25th, 2024
Abiologics Appoints Maria-Chiara Magnone as Chief Scientific Officer

Magnone joins Abiologics from Johnson & Johnson (J&J), where she was initially Vice President, Kidney Disease Research and Boston Site Head, and more recently Vice President, Head of Discovery for the Cardiovascular, Metabolic, Retina and Pulmonary Hypertension therapeutic area.

UMass Boston
Sep 19th, 2024
Life Sciences Inventor, CEO Avak Kahvejian Offers a Path to Innovation and Inspiration at Convocation

He spoke of how UMass Boston is collaborating with Abiologics, the newest of the three Flagship companies operating out of South Line, sharing specialized equipment along with expertise.

PR Newswire
Jul 23rd, 2024
Flagship Pioneering Unveils Abiologics To Pioneer Supranatural Biologics, A New Biotherapeutic Class

The Abiologics platform leverages cutting-edge generative AI and high throughput chemical protein synthesis to create Synteins™, a new class of programmable medicines that aims to redefine what therapeutics can achieve for patientsThe company emerges after 3 years of platform development and an initial commitment of $50 million from Flagship PioneeringCAMBRIDGE, Mass., July 23, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Abiologics, a company reimagining biologics with the creation of a new class of supranatural and programmable medicines, called Synteins™. Synteins are computationally-generated and synthesized with novel building blocks, endowing them with extraordinary properties to bring life-changing treatments to patients across a wide range of diseases. Flagship has initially committed $50 million to advance the company's platform and develop a diverse pipeline of medicines, with an initial focus on oncology and immunology indications.Abiologics"Biologics have transformed medicine in the past forty years, but only a fraction of their potential has been realized because we've been limited by the boundaries of nature," said Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering and Co-Founder and Chairman of the Strategic Oversight Board of Abiologics. "With the convergence of advancements in generative artificial intelligence, automated polymer synthesis and chemical functionalization coupled with a vision to develop more powerful medicines with unprecedented diversity, we asked, what if we could design biologics entirely from new building blocks that could overcome the most critical limitations of today's medicines?"The Abiologics platform is a fully integrated digital and automated wet-lab infrastructure to create supranatural biologics with powerful, desirable pharmacological properties. The platform leverages state-of-the-art generative artificial intelligence (AI) to computationally-design Synteins de novo using a broad set of artificial building blocks, far beyond the 20 naturally occurring amino acids that form the basis of today's biologic medicines. These include biologics built with D-amino acids, chemically identical mirror images of standard amino acids